BIOTRON LIMITED(BIT.AU)

0.00+0.00-25.00%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- New Zealand Shares End Lower Amid Silver Reaching Record Highs; Bankers Investment Trust Reports Net Asset Value
  MT Newswires Live · 2025-12-29
  New Zealand Shares End Lower Amid Silver Reaching Record Highs; Bankers Investment Trust Reports Net Asset Value
- Biotron Ltd-Director Appointment DR Paul Kasian & Appendix 3X
  THOMSON REUTERS · 2025-12-23
  Biotron Ltd-Director Appointment DR Paul Kasian & Appendix 3X
- Biotron Ltd-Chair's Address to Shareholders
  THOMSON REUTERS · 2025-11-17
  Biotron Ltd-Chair's Address to Shareholders
- Biotron Ltd-Hepatitis B Virus Program Update
  THOMSON REUTERS · 2025-11-14
  Biotron Ltd-Hepatitis B Virus Program Update
- BUZZ-Australia's biotech firm Biotron rises on Sedarex acquisition
  Reuters · 2025-10-15
  BUZZ-Australia's biotech firm Biotron rises on Sedarex acquisition
- BRIEF-Biotron To Raise A$2.5 MLN Through 2 Tranche Placement At A$0.003 Per Share
  Reuters · 2025-10-15
  BRIEF-Biotron To Raise A$2.5 MLN Through 2 Tranche Placement At A$0.003 Per Share
- Biotron Ltd-Proposed Issue of Securities - Bit
  THOMSON REUTERS · 2025-10-15
  Biotron Ltd-Proposed Issue of Securities - Bit
- Biotron Ltd - All Currencies in AUD
  THOMSON REUTERS · 2025-10-15
  Biotron Ltd - All Currencies in AUD
- Biotron Ltd - to Raise Through 2 Tranche Placement at a$0.003 per Share
  THOMSON REUTERS · 2025-10-15
  Biotron Ltd - to Raise Through 2 Tranche Placement at a$0.003 per Share
- Biotron Ltd-Acquisition of Sedarex Limited and $2.5M Capital Raising
  THOMSON REUTERS · 2025-10-15
  Biotron Ltd-Acquisition of Sedarex Limited and $2.5M Capital Raising
- BRIEF-Biotron Requests Trading Halt Pending Material Acquisition, Capital Raising Announcement
  Reuters · 2025-10-13
  BRIEF-Biotron Requests Trading Halt Pending Material Acquisition, Capital Raising Announcement
- Director Appointment Michael Medway-BIT.AX
  Reuters · 2025-07-16
  Director Appointment Michael Medway-BIT.AX
Company Profile
Company Name
BIOTRON LIMITED
Market
ASX
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.biotron.com.au
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, including Dengue, Zika, Influenza, Ebola, and SARs. Biotron Limited is based in North Ryde, Australia.

1D
5D
Day
Week
Month

Loading ...

High

0.00

Open

0.00

Volume%

2.58

Low

0.00

T/O Rate

0.65%

To The Moon

BIOTRON LIMITED(BIT.AU)

Company Profile

Most Discussed